Sulindac sulfide, a metabolite of the nonsteroidal antiin-( ) flammatory drug NSAID sulindac sulfoxide, is effective at reducing tumor burden in both familial adenomatous polyposis patients and in animals with colorectal cancer. Another sulindac sulfoxide metabolite, sulindac sulfone, has been reported to have antitumor properties without inhibiting cyclooxygenase activity. Here we report the effect of sulindac sulfone treatment on the growth of colorectal carcinoma cells. We observed that sulindac sulfide or sulfone treatment of HCA-7 cells led to inhibition of prostaglandin E production. Both sulin-2 dac sulfide and sulfone inhibited HCA-7 and HCT-116 cell growth in vitro. Sulindac sulfone had no effect on the growth of either HCA-7 or HCT-116 xenografts, whereas the sulfide derivative inhibited HCA-7 growth in vivo. Both sulindac sulfide and sulfone inhibited colon carcinoma cell growth and prostaglandin production in vitro, but sulindac sulfone had no effect on the growth of colon cancer cell xenografts in nude mice.
Introduction
Colorectal cancer remains a significant health concern for much of the industrialized world. Diagnosis often occurs at a late stage in the progression of this disease, which reduces the likelihood of effective treatment. Current treatment strategies often involve a combination of surgical resection and adjuvant therapy. Because of the unsatisfactory outcome of existing treatment methods, much emphasis has been placed on developing new treatment and prevention strategies.
Numerous epidemiologic studies indicate that chronic use of low-dose nonsteroidal antiinflammatory drugs ( ) [ ] NSAIDs are chemopreventive for colorectal cancer 1,2 . NSAIDs cause regression of existing polyps in familial ade-( ) nomatous polyposis FAP patients and reduce the tumor [ ] burden in animal models of colorectal cancer 3 -6 . NSAIDs ( ) inhibit the activity of the cyclooxygenases COX , which are ( ) key enzymes in prostaglandin PG production. Unfortunately, prolonged NSAID use can result in side effects such as gastrointestinal ulceration and bleeding. It is widely believed that this ulcerogenic activity is due to chronic inhibition of PG production via COX-1 inhibition in the gastric mucosa. Accordingly, researchers have tried to identify NSAID derivatives that retain antitumor activity but do not affect PG production in gastric mucosa.
Sulindac sulfoxide is a prodrug that is reduced in vivo to sulindac sulfide or oxidized to sulindac sulfone. The sulfide derivative effectively inhibits the COX enzymes. Sulindac sulfone does not interfere with COX activity when applied to ( )[] the recombinant enzyme in vitro data not shown 7 . Studies in which colorectal cancer cell lines were treated with high doses of either sulfide or sulfone indicated that both derivatives can induce apoptosis and alter proliferation [ ] rates 7 . There is evidence that sulindac sulfone can induce apoptosis in cell lines that do not express either COX-1 or [ ] COX-2 7 . Accordingly, the mechanism of action of this compound, at the effective doses, is independent of any possible interaction with COX in these cells. Because sulindac sulfone does not appear to inhibit the COX activity and can induce apoptosis in colorectal cancer cell lines independent of COX expression, it held some promise as a potential chemopreventive agent for colorectal cancer with improved safety over NSAIDS.
It has previously been reported that sulindac sulfone is capable of reducing the incidence, multiplicity and tumor ( ) burden in the azoxymethane AOM rat model of colorectal [ ] cancer 8 . In another animal model, the Min mouse, sulindac sulfone had no effect on polyp number or size whereas sulindac sulfide was quite effective in causing polyp regres-[ ] sion 4 . In both studies, drug treatment was initiated before a lesion had developed. In this study we tested the hypothesis that sulindac sulfone can inhibit the growth of highly malignant colorectal carcinoma cells in both in vitro and in vivo tumor models. These studies may help to clarify the potential in vivo effectiveness of sulindac sulfone in colorectal cancer treatment.
Materials and Methods

Reagents
Sulindac sulfide and sulindac sulfone were obtained from ( ) Merck and Co, Rahway, NJ, and dimethyl sulfoxide DMSO ( ) EM Science, Gibbstown, NJ was used as the solvent. Concentrated drug stocks were diluted in Dulbecco's modi-( ) ( fied Eagle's medium DMEM GIBCO-BRL, Grand Island, ) NY before addition to cell cultures. The DMSO concentration in cultures was kept at 0.1%, and the purity of sulindac sulfone was verified by NMR.
Prostaglandin Measurement
Subconfluent cell cultures were treated with the indicated compound for 24 hours. One hour before harvesting, arachidonate was added to the media to a final concentration of 10 mmol / L along with fresh drug. Eicosanoids were quantified in media from cell incubations by using stable isotope dilution techniques with gas chromatography negative ion chemical ionization-mass spectrometry, as previously The cells were trypsinized and resus-( ) pended in sterile phosphate buffered saline PBS and then pelleted by brief centrifugation at 1500 rpm. The supernant was aspirated and cells were resuspended in PBS and counted with a hemocytometer. A final concentration of 5 = 10 7 cells / mL was made and 100 mL of cell suspension was injected subcutaneously with a tuberculin syringe and a 27-gauge needle. For both HCA-7 and HCT-116 cell lines animals were randomly divided into treatment and control arms, with five animals in each group. In the sulindac sulfide experiments seven animals were included in each group. Treatment was initiated at the time the tumors were im- planted with the exception of the sulindac sulfide treatment group in which treatment was delayed until the tumor was ( ) established 7 weeks . When no effect was observed on tumor growth with sulindac sulfone treatment, the amount of sulfone was increased until a maximal dose of 100 mg / kg was achieved by week 5. The size of the tumor was determined at 1-week intervals by direct measurement. The 
Statistical Methods
Student's t-test was used to determine significant differences in in vitro assays. In the xenograft experiments, ANOVA with repeated measures was employed to evaluate the significance of drug treatment on tumor growth.
Results
Effect of Sulindac Sulfone on Prostaglandin E Production 2 in HCA-7 Cells
Sulindac sulfide, the active metabolite of sulindac, inhibits the enzymatic activity of recombinant COX-1 and COX-2. It has been reported that sulindac sulfone does not inhibit the activity of either COX isoform using recombinant [ ] enzyme assay 7 . We confirmed this by testing the effect of sulfone on recombinant COX activity and saw no change in ( ) ( ) Figure 4 . Sulindac sulfone does not alter the growth of HCA-7 or HCT-116 xenografts. HCA-7 A or HCT-116 B cells were grown to 70 % confluence and then trypsinized; 5 = 10 6 cells were injected subcutaneously into the dorsal flank of athymic mice. The mice were divided into treatment and control groups. The initial dose of sulindac sulfone was 10 mg / kg and then increased to 100 mg / kg by week 5. The volume of the tumor was calculated (
according to the equation V s L = W = 0.5 , where V s volume, L s length, and W s width insert . HCA-7 cells 5 = 10 cells were xenograft into nude mice. After 7 weeks of tumor growth intraperitoneal injections with sulindac sulfide were initiated at a dose of 10 mg / kg every otherenzyme activity even when millimolar amounts of drug were ( ) added data not shown . However, it is possible that in vitro the sulfone derivative may affect other steps in the eicosanoid biosynthetic pathway. Therefore, we tested whether or not sulfone treatment altered PGE levels in a 2 colorectal cancer cell line, HCA-7, which expresses high levels of COX-2. As expected, 25 mmol / L sulfide treatment reduced PGE levels by 95%. However, to our surprise, whether or not the decrease in PG synthesis was limited to PGE we tested the effect of sulfone treatment on PG 2 ( ) production in rat intestinal epithelial RIE cells overexpressing COX-2, which produce mainly prostacyclin. Levels of 6-ketoPGF a , the stable metabolite of prostacyclin, were 1 measured after treatment with either sulindac sulfide or sulfone. Sulindac sulfide at 25 mmol / L reduced 6-keto PGF a levels by 73.5% and sulindac sulfone at 100 mmol / L 1 reduced 6-ketoPGF a by 29.2%. Therefore, inhibition of PG 1 production by sulindac sulfone in vitro is not specific to one class of PGs. There was no detectable COX-1 in HCA-7 cells and neither sulindac sulfide nor sulfone affected COX-2 ( ) expression Figure 2 . Therefore, the decrease in PG production did not result from alterations in steady state levels of COX-2.
Effect of Sulindac Sulfone or Sulfide on Colorectal Cancer Cell Colony Growth in Matrigel
Because sulindac sulfone decreased PG levels in cultured HCA-7 cells we tested whether sulfone impaired the ability of HCA-7 or HCT-116 cells to form discrete colonies in Matrigel. HCA-7 cells express high levels of COX-2, whereas there is no detectable COX-1 or COX-2 protein in [ ] HCT-116 cells 12 . COX-2 selective inhibitors reduce the growth of HCA-7 cells in Matrigel,whereas there is no effect on the growth of HCT-116 cells. Each cell line was plated in triplicate in Matrigel mixed with the indicated amount of ( ) either sulindac sulfide, sulfone, or vehicle DMSO . Both HCA-7 and HCT-116 cells showed equivalent reductions in ( colony number with sulfone or sulfide treatment sulfone ( ) EC f 50 mmol / L, sulfide EC -50 mmol / L Figure 3A , 50 50 however, HCA-7 colony size was much more sensitive than ( HCT-116 to treatment with either sulfone or sulfide Student t-test at 25 mmol / L: sulfone, P -.01; sulfide, P -.0001; ) Figure 3C .
Treatment of COX-2-Positive and Negative Colorectal Cancer Cell Xenografts with Sulindac Sulfone
Because sulindac sulfone inhibited the in vitro growth of HCA-7 and HCT-116 cells, we sought to test whether sulindac sulfone altered the in vivo growth of either cell line by using a xenograft tumor model. HCA-7 or HCT-116 cells were implanted into the dorsal flank of nude mice. We have found that in this model NSAIDs reduce tumor growth when given every other day at doses between 5 to 10 mg / kg. Therefore, immediately preceding tumor cell implantation an initial dose of 10 mg / kg of sulfone was injected intraperitoneally. This dose was repeated every other day, and tumor dimensions were measured at weekly intervals as shown in Figure 4 . No effect was observed on either HCA-7 or HCT-116 tumor growth after 2 weeks of sulfone treatment at this dosing regimen. Previously, we have observed a significant difference in tumor size after 2 weeks of treatment of HCA-7 xenografts with selective inhibitors of COX-2 [ ] 12,14 . Therefore, the amount of sulfone was increased until a maximal dose of 100 mg / kg was achieved by week 5. Throughout the duration of this experiment no differences in tumor volume were observed with sulfone treatment in either HCA-7 or HCT-116 xenografts.
A more rigorous test of the chemotherapeutic potential of a drug is to test its effect on the growth of established xenografts. This removes the possibility of the drug interfering with tumor implantation and directly measures the ability of a compound to influence the growth of an established tumor. Sulindac sulfide was used at a dose of 10 mg / kg every other day to treat HCA-7 xenografts that had been implanted 7 weeks earlier. In this experiment, a significant reduction in tumor growth was observed within 2 weeks of ( ) treatment initiation Figure 4A , insert .
To measure the COX expression profile of HCA-7 and HCT-116 xenografts, tumor lysates were made and Western blotting analysis was done with COX-1 or COX-2 selective antibodies. In agreement with previous reports, HCA-7 xenografts expressed COX-2 but not COX-1 protein, and HCT-116 tumors contained neither COX-1 nor COX-2 pro-( )[ ] tein Figure 5 12 .
Prostaglandin Measurements in HCA-7 Xenografts
Although a significant change in tumor size was not observed with sulfone treatment, we assessed the effect of the sulfone on PGE production in the HCA-7 xenografts. with and without sulindac sulfone treatment as determined by stable isotope dilution techniques with gas chromatography negative ion chem-( ) ical ionization-mass spectrometry see methods .
[ ] reported to be elevated in colorectal cancers 15 . At necropsy the tumors were assayed for PGE levels. Sulin-2 dac sulfone treatment had no effect on the PGE levels in 2 ( ) ( either HCA-7 Figure 6 or HCT-116 xenografts data not ) shown . [ ] reducing tumor multiplicity 4 . Both AOM rat and Min mouse studies were designed to test the ability of the sulfone derivative to prevent tumor growth in a setting in which normal epithelium is induced to a transformed state by either carcinogen exposure or by the presence of a preexisting genetic mutation. In this study, we tested the effect of sulfone treatment on the growth of colorectal cancer cells by using both in vitro and in vivo growth assays. We have previously found that selective COX-2 inhibitors block tumor growth in this model.
Discussion
We found that sulindac sulfone did not modify the growth of colorectal cancer cells xenografted into nude mice. In order to control the dose given to individual animals and to increase the likelihood that sulfone would enter the circulation and thus reach the tumor site, we chose to deliver the drug by intraperitoneal injection. There was no effect on tumor growth observed in either HCA-7 or HCT-116 xenografts, even when doses of 100 mg / kg were given. In humans, sulindac sulfide has a serum half-life of 13 to 14 hours, and sulindac sulfone has a longer serum half-life of [ ] 20 to 22 hours 19,20 , suggesting that differences in the chemotherapeutic potential of these compounds is not due to rapid clearance of sulindac sulfone. Furthermore, similar studies with selective inhibitors of COX-2 such as SC-58125 or meloxicam at 7.5 mg / kg and 40 mg / kg, respectively, inhibited tumor growth within 2 weeks of starting treatment [ ] 12,14 . Additionally, sulindac sulfide effectively inhibited tumor growth within 2 weeks of initiating treatment.
An alternative explanation for sulindac sulfone's lack of an effect on tumor growth may be a requirement for gut specific cofactors in order for an antineoplastic effect in vivo. However, sulindac sulfone is able to induce apoptosis and inhibit the in vitro growth of colorectal cancer cells [ ] 7,21 in the absence of gut-derived cofactors and sulindac sulfone is effective at inhibiting the in vitro and in vivo [ ] growth of nongastrointestinal-derived cancers 22 . Furthermore, sulindac sulfone has no effect on tumor growth in the Min mouse. In this model the tumors arise in the gastrointestinal tract and are exposed to luminal contents during drug treatment.
In agreement with previous reports, by using in vitro growth assays, we found that sulindac sulfone could inhibit the growth of HCA-7 and HCT-116 cells. We observed a decrease in both the size and number of HCA-7 colonies grown in artificial matrix, suggesting that sulindac sulfone inhibits colony formation and alters the growth characteristics of surviving colonies, possibly by altering the balance between cell proliferation and programmed cell death.
If sulindac sulfone does not directly inhibit the activity of recombinant COX, then why is a reduction in PGs observed when HCA-7 cells are treated with sulindac sulfone? It is possible that sulfone treatment could affect the activity of PG synthases, but this seems unlikely because sulindac sulfone also inhibited the production of prostacyclin in RIE-COX-2 cells and PGE by RKO cells transiently trans-2 ( ) fected with rat COX-2 data not shown . Decreasing the steady state levels of COX-2 in HCA-7 cells could result in decreased PG production. We determined by Western blotting that sulindac sulfone did not influence either COX-1 or COX-2 protein levels in HCA-7 cells. It has been reported ( that sulindac sulfone can inhibit phospholipase A 15% at 2 ) [ ] 0.1 -1000 mmol / L 8 . In our experiments, we added exogenous arachidonate to the cell culture media 1 hour before obtaining samples for PG determination; it is unlikely that inhibition of PLA activity by sulindac sulfone could 2 affect PG production under these circumstances.
Why does sulindac sulfone inhibit colorectal cancer cell growth in in vitro assays and yet have no effect on the growth of the cells in the tumor xenograft model? Tumor xenograft assays evaluate a compound's effectiveness in the setting of whole animal physiology. Clearance, bioavailability, and biotransformation may attenuate or amplify a compound's effect on the tumor's biological characteristics. Furthermore, in vivo assays test the ability of a compound to inhibit tumor growth in an environment where tumor/ stromal interactions are occurring. It is possible that the ( ) pathway or pathway s by which sulfone inhibits the growth of HCA-7 and HCT-116 cells in vitro are compensated for by stromal-derived signals present in an in vivo system. 
